Barinthus Biotherapeutics (BRNS) Total Non-Current Liabilities (2021 - 2026)

Barinthus Biotherapeutics has reported Total Non-Current Liabilities for 6 years, with the latest figure at $22.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 9.17% year-over-year to $22.7 million; the trailing twelve-month figure through Mar 2026 stood at $22.7 million (down 9.17% YoY), and the FY2025 full-year result was $22.4 million, down 18.67% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $22.7 million, up from $22.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $32.6 million in Q3 2023, with the low at $22.4 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $26.9 million across 5 years, with a median of $26.5 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities increased 6.38% — and 2025, when it fell 18.67%.
• Barinthus Biotherapeutics' Total Non-Current Liabilities stood at $26.0 million in 2022, then rose by 0.56% to $26.2 million in 2023, then advanced by 5.18% to $27.5 million in 2024, then slipped by 18.67% to $22.4 million in 2025, then gained by 1.37% to $22.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $22.7 million (Q1 2026), $22.4 million (Q4 2025), and $23.2 million (Q3 2025), per Business Quant data.